Cargando…

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis

IMPORTANCE: Patients who are immunocompromised have increased risk for morbidity and mortality associated with coronavirus disease 2019 (COVID-19) because they less frequently mount antibody responses to vaccines. Although neutralizing anti-spike monoclonal-antibody treatment has been widely used to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Senefeld, Jonathon W., Franchini, Massimo, Mengoli, Carlo, Cruciani, Mario, Zani, Matteo, Gorman, Ellen K., Focosi, Daniele, Casadevall, Arturo, Joyner, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857047/ https://www.ncbi.nlm.nih.gov/pubmed/36633846 http://dx.doi.org/10.1001/jamanetworkopen.2022.50647

Ejemplares similares

WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
por: Franchini, Massimo, et al.
Publicado: (2023)

Convalescent plasma for COVID-19 in oncohematological patients: a call for revision of the European Conference on Infections in Leukemia-9 (ECIL-9) guidelines
por: Focosi, Daniele, et al.
Publicado: (2023)

Convalescent plasma for COVID-19. TSUNAMI is not the final word
por: Franchini, Massimo, et al.
Publicado: (2022)

Convalescent plasma to deliver therapeutic antibodies against COVID-19
por: Senefeld, Jonathon W., et al.
Publicado: (2022)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J, et al.
Publicado: (2022)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J., et al.
Publicado: (2023)

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J, et al.
Publicado: (2022)

Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
por: Bloch, Evan M, et al.
Publicado: (2023)

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
por: Focosi, Daniele, et al.
Publicado: (2022)

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J., et al.
Publicado: (2022)

On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
por: Focosi, Daniele, et al.
Publicado: (2022)

Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews
por: Franchini, Massimo, et al.
Publicado: (2021)

Convalescent plasma in outpatients with COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
por: Focosi, Daniele, et al.
Publicado: (2021)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality
por: Casadevall, Arturo, et al.
Publicado: (2021)

Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
por: Focosi, Daniele, et al.
Publicado: (2022)

How Safe Is COVID-19 Convalescent Plasma?
por: Franchini, Massimo, et al.
Publicado: (2021)

Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Plasma Hesitancy cost lives?
por: Casadevall, Arturo, et al.
Publicado: (2021)

Use of convalescent plasma in the treatment of COVID-19
por: Joyner, Michael J., et al.
Publicado: (2023)

The emergency use authorization for COVID‐19 convalescent plasma reduced mortality
por: Paneth, Nigel, et al.
Publicado: (2023)

SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
por: Casadevall, Arturo, et al.
Publicado: (2023)

Late Treatment for COVID-19 With Convalescent Plasma
por: Senefeld, Jonathon W., et al.
Publicado: (2022)

Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors
por: Franchini, Massimo, et al.
Publicado: (2021)

Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19
por: Ripoll, Juan G., et al.
Publicado: (2021)

Polyclonal immunoglobulins for COVID-19 pre-exposure prophylaxis in immunocompromised patients
por: Focosi, Daniele, et al.
Publicado: (2023)

In Reply—How Safe Is COVID-19 Convalescent Plasma?
por: Joyner, Michael J., et al.
Publicado: (2021)

In Reply — Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Joyner, Michael. J., et al.
Publicado: (2020)

Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19
por: Ripoll, Juan G., et al.
Publicado: (2022)

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
por: Thompson, Michael A., et al.
Publicado: (2021)

Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy
por: Casadevall, Arturo, et al.
Publicado: (2020)

Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency
por: Focosi, D., et al.
Publicado: (2021)

HLA Antibody Rates Are Not Increased in a Regional Group of Male COVID-19 Convalescent Plasma Donors
por: Juskewitch, Justin E., et al.
Publicado: (2021)

The Assessment of Convalescent Plasma Efficacy against COVID-19
por: Casadevall, Arturo, et al.
Publicado: (2020)

Use of convalescent plasma in COVID‐19 patients with immunosuppression
por: Senefeld, Jonathon W., et al.
Publicado: (2021)

Efficacy of High-Dose Polyclonal Intravenous Immunoglobulin in COVID-19: A Systematic Review
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence
por: Klassen, Stephen A., et al.
Publicado: (2021)

The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
por: Focosi, Daniele, et al.
Publicado: (2021)

Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor–recipient differences in concentration of neutralizing antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients—An Open-Label Phase II Clinical Trial
por: Grubovic Rastvorceva, Rada M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pjm40040fh7mjd9tp241ct8b4n